Get the Stockscreener App
0.1679
2.55%
-0.0044
After Hours:
.17
0.0021
+1.25%
Bioatla Inc stock is traded at $0.1679, with a volume of 838.40K.
It is down -2.55% in the last 24 hours and down -11.68% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.1723
Open:
$0.17
24h Volume:
838.40K
Relative Volume:
0.37
Market Cap:
$12.47M
Revenue:
$11.00M
Net Income/Loss:
$-64.71M
P/E Ratio:
-0.1461
EPS:
-1.1496
Net Cash Flow:
$-57.52M
1W Performance:
-29.28%
1M Performance:
-11.68%
6M Performance:
-68.70%
1Y Performance:
-52.03%
1-Day Range:
$0.1625
$0.1705
1-Week Range:
$0.161
$0.265
52-Week Range:
$0.13
$1.43
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.1679 | 12.80M | 11.00M | -64.71M | -57.52M | -1.1496 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
BioAtla (BCAB) CFO sees 1,802 shares withheld for RSU tax settlement - Stock Titan
[Form 4] BioAtla, Inc. Insider Trading Activity - Stock Titan
BioAtla (BCAB) CMO reports 3,140-share tax withholding on RSU vesting - Stock Titan
BioAtla explores sale as it cuts 70% of workforce - Investing.com
BioAtla launches major restructuring and leadership transition - TipRanks
BioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder Value - Quiver Quantitative
BioAtla Inc announces 70% workforce reductionSEC filing - marketscreener.com
BioAtla appoints Chris Vasquez as CFO as Richard Waldron departs - TradingView
BioAtla (NASDAQ: BCAB) slashes workforce 70% amid strategic review, listing risk - Stock Titan
Bioatla announces formal process to evaluate strategic options to monetize assets - marketscreener.com
Bioatla Announces Formal Process To Evaluate Strategic Options To Monetize Assets - TradingView
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets - marketscreener.com
BCAB PE Ratio & Valuation, Is BCAB Overvalued - Intellectia AI
US Market Wrap: Does BioAtla Inc meet Warren Buffetts criteria2025 Retail Activity & Low Drawdown Momentum Ideas - baoquankhu1.vn
Aug Sentiment: Is BioAtla Inc forming bullish engulfing patterns2025 Geopolitical Influence & Long-Term Safe Return Strategies - baoquankhu1.vn
BioAtla (BCAB) CEO has shares withheld to cover RSU taxes - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BioAtla to Participate in the Citizens Life Sciences Conference - 富途牛牛
Gap Down: Will BioAtla Inc stock hit new highs in YEAR2025 Bull vs Bear & Accurate Intraday Trading Signals - baoquankhu1.vn
BCABBioatla, Inc. Latest Stock News & Market Updates - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Aug Chart Watch: Will Nixxy Inc Equity Warrant outperform its industry peers2025 Trading Volume Trends & Accurate Buy Signal Alerts - baoquankhu1.vn
Why BioAtla Inc. stock is popular among millennials2025 Pullback Review & Entry and Exit Point Strategies - mfd.ru
What analysts say about BioAtla Inc. stockJuly 2025 Review & Growth Focused Stock Reports - mfd.ru
BCAB Should I Buy - Intellectia AI
BioAtla Sets March Virtual Vote on Internal Merger Plan - The Globe and Mail
Why BioAtla Inc. stock could see breakout soonSell Signal & Community Consensus Picks - mfd.ru
BioAtla (BCAB) seeks approval for 1‑for‑50 share conversion to support Nasdaq listing - Stock Titan
Bioatla Faces Nasdaq Delisting Review Amid Corporate Restructuring - AD HOC NEWS
Is BioAtla Inc. currently under institutional pressureQuarterly Risk Review & Technical Analysis for Trade Confirmation - mfd.ru
BioAtla Faces Nasdaq Review of Continued Listing Status - The Globe and Mail
BioAtla to remain on Nasdaq during listing council review process By Investing.com - Investing.com Canada
BioAtla to remain on Nasdaq during listing council review process - Investing.com
BioAtla Faces Nasdaq Delisting Review - TradingView
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
BioAtla Faces Nasdaq Trading Suspension and Potential Delisting - The Globe and Mail
BioAtla to be suspended from Nasdaq after delisting determination By Investing.com - Investing.com Nigeria
BioAtla to be suspended from Nasdaq after delisting determination - Investing.com
BioAtla Received Notice of Delisting - TradingView
Activity Recap: Will BioAtla Inc benefit from AI trends2025 Biggest Moves & Precise Buy Zone Tips - baoquankhu1.vn
BioAtla sets merger plan after Nasdaq rule change affects reverse split vote By Investing.com - Investing.com South Africa
BioAtla sets merger plan after Nasdaq rule change affects reverse split vote - Investing.com Australia
BioAtla (BCAB) seeks approval for 1-for-50 share conversion and charter changes - stocktitan.net
BioAtla Pursues Share Consolidation Amid Nasdaq Compliance Dispute - TipRanks
Street Watch: What is the dividend yield of BioAtla IncGold Moves & Reliable Momentum Entry Alerts - baoquankhu1.vn
Is BioAtla Inc. a turnaround story2025 Biggest Moves & Verified Technical Trade Signals - mfd.ru
EPS Watch: Will BioAtla Inc stock hit new highs in YEARWeekly Profit Report & Smart Investment Allocation Tips - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Aug Mood: Will BioAtla Inc stock hit new highs in YEAR2025 Earnings Impact & Real-Time Volume Analysis - baoquankhu1.vn
Aug Sectors: Is BioAtla Inc forming bullish engulfing patternsJuly 2025 Outlook & Weekly Chart Analysis and Guides - baoquankhu1.vn
Aug Chart Watch: What is the dividend yield of BioAtla IncWatch List & Technical Buy Zone Confirmations - baoquankhu1.vn
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):